Charlotta Ljungman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charlotta Ljungman has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Karin Manhem
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
4 shared publications - Linus Schiöler
Department of Occupational and Environmental Medicine, School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
4 shared publications - Thomas Kahan
Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
4 shared publications - Jan Hasselström
Department of Neurobiology, Care Sciences and Society, Section of Family Medicine and Primary Care, Karolinska Institutet
3 shared publications - Per Hjerpe
General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , 405 30 Gothenburg
3 shared publications Araz Rawshani
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg
2 shared publications
Latest Publications
- 2 September 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry
Aims: The interactions between heart failure (HF), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and relative drug use remain poorly studied. Methods: Patients enrolled in the Swedish HF registry 2017–2023 were divided according to CKD and T2DM. HF medication use and all-cause death, cardiovascular death, first HF hospitalization (HHF), their composite, and end-stage renal disease (ESRD) were assessed. Results: Among 54 341 patients (34% females, mean age 73 years), 51% had no CKD/no T2DM, 24% CKD only, 14% T2DM only, and 11% both CKD/T2DM. CKD only and CKD/T2DM prevalences were higher in HF with preserved ejection fraction (HFpEF; 29% and 15%, respectively) than with mildly reduced EF (HFmrEF; 23% and 11%) and reduced EF (HFrEF 22% and 10%). HF medication use, especially of mineralocorticoid receptor antagonists, was generally lower in groups with CKD. Event rates for all outcomes were progressively higher going from no CKD/no T2DM, T2DM only, CKD only, and both CKD/T2DM in all EF categories. Independent risks of mortality and HF outcomes were significantly increased in the presence of CKD/T2DM, whereas for ESRD, T2DM alone did not significantly increase risk, CKD alone increased it threefold, and both CKD and T2DM increased it six-fold. CKD added more to the risk of events in HFrEF than in HFpEF. Conclusion: CKD was more common in HFpEF and a strong independent risk factor for all outcomes. T2DM was a moderate independent risk factor for all outcomes. These findings inform drug implementation and future aldosterone-targeting drug trials.
- 2 September 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry
Aims: The interactions between heart failure (HF), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and relative drug use remain poorly studied. Methods: Patients enrolled in the Swedish HF registry 2017–2023 were divided according to CKD and T2DM. HF medication use and all-cause death, cardiovascular death, first HF hospitalization (HHF), their composite, and end-stage renal disease (ESRD) were assessed. Results: Among 54 341 patients (34% females, mean age 73 years), 51% had no CKD/no T2DM, 24% CKD only, 14% T2DM only, and 11% both CKD/T2DM. CKD only and CKD/T2DM prevalences were higher in HF with preserved ejection fraction (HFpEF; 29% and 15%, respectively) than with mildly reduced EF (HFmrEF; 23% and 11%) and reduced EF (HFrEF 22% and 10%). HF medication use, especially of mineralocorticoid receptor antagonists, was generally lower in groups with CKD. Event rates for all outcomes were progressively higher going from no CKD/no T2DM, T2DM only, CKD only, and both CKD/T2DM in all EF categories. Independent risks of mortality and HF outcomes were significantly increased in the presence of CKD/T2DM, whereas for ESRD, T2DM alone did not significantly increase risk, CKD alone increased it threefold, and both CKD and T2DM increased it six-fold. CKD added more to the risk of events in HFrEF than in HFpEF. Conclusion: CKD was more common in HFpEF and a strong independent risk factor for all outcomes. T2DM was a moderate independent risk factor for all outcomes. These findings inform drug implementation and future aldosterone-targeting drug trials.
- Open Access
- 5 March 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (4) , 621-630
Enhancing heart failure care through registries: lessons learned from Nordic Countries’ implementation of guidelines
This review evaluates the role of heart failure (HF) registries in the Nordic countries—Sweden, Denmark, Norway, and Iceland—in the implementation of the European Society of Cardiology's guidelines for guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF). It critically examines how these registries facilitate clinical practice and enhance patient outcomes through their design, data collection methods, and the evaluation of key metrics related to GDMT implementation over time. We highlight the nurse-led models adopted by these registries, which emphasize quality benchmarks and feature real-time feedback mechanisms regarding the application of GDMT. Between 2021 and 2024, registry population-weighted estimates revealed significant increases in the utilization of key therapies: mineralocorticoid receptor antagonists rose from 51% to 72%, sodium-glucose co-transporter-2 inhibitors from 20% to 81%, and sacubitril/valsartan from 22% to 32%. The use of beta-blockers and renin-angiotensin-system inhibitors remained consistently high at 91% and 94%, respectively. These shifts were linked to better treatment outcomes. The findings underscore that HF registries play a crucial role in enhancing care quality through established drug therapies for HFrEF, offering a model for integrating data-driven methodologies into HF management. Future utilization and expansion of these registries are vital for tackling healthcare disparities and refining treatment strategies for HF patients.
- 5 March 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (4) , 621-630
Open AccessEnhancing heart failure care through registries: lessons learned from Nordic Countries’ implementation of guidelines
This review evaluates the role of heart failure (HF) registries in the Nordic countries—Sweden, Denmark, Norway, and Iceland—in the implementation of the European Society of Cardiology's guidelines for guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF). It critically examines how these registries facilitate clinical practice and enhance patient outcomes through their design, data collection methods, and the evaluation of key metrics related to GDMT implementation over time. We highlight the nurse-led models adopted by these registries, which emphasize quality benchmarks and feature real-time feedback mechanisms regarding the application of GDMT. Between 2021 and 2024, registry population-weighted estimates revealed significant increases in the utilization of key therapies: mineralocorticoid receptor antagonists rose from 51% to 72%, sodium-glucose co-transporter-2 inhibitors from 20% to 81%, and sacubitril/valsartan from 22% to 32%. The use of beta-blockers and renin-angiotensin-system inhibitors remained consistently high at 91% and 94%, respectively. These shifts were linked to better treatment outcomes. The findings underscore that HF registries play a crucial role in enhancing care quality through established drug therapies for HFrEF, offering a model for integrating data-driven methodologies into HF management. Future utilization and expansion of these registries are vital for tackling healthcare disparities and refining treatment strategies for HF patients.
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039248
Metabolite Profiles of Heart Failure, Central Hemodynamic Derangement, and Response to Heart Transplantation
Background: Heart failure (HF) is characterized by hemodynamic derangements that are likely to mediate systemic metabolic perturbations but limited data are available. Plasma metabolite profiling provides opportunities for comprehensive investigation of such perturbations. Here, we aimed to characterize plasma profiles that associate with HF and their relationship with central hemodynamics, symptom burden, and response to restoration of cardiac function by heart transplantation. Methods: Untargeted metabolite profiling was conducted with mass spectrometry in 2 independent case–control samples. Results: In total, 89 of 797 studied metabolites were significantly associated with HF in both cohorts with concordant directionality. Amino acid, carbohydrate, and nucleotide metabolites were enriched for association with HF and were consistently increased in HF cases. A subset of patients with advanced HF subsequently underwent heart transplantation, after which 17 of the 89 metabolites returned significantly toward healthy control levels. These 17 metabolites represent increased catecholamine and heme metabolism, conjugated bile acids, kynurenine pathway mediators, spermidine metabolism, and allantoin, as well as tricarboxylic acid cycle and glycolysis intermediates. Most of these metabolites associated with symptom burden and at least 1 of 12 central hemodynamic parameters, primarily relating to either increased systemic or pulmonary venous congestion, lower cardiac output, or lower left ventricular stroke work. Conclusions: We comprehensively identified metabolite profiles associated with HF and central hemodynamics that reverse by cardiac transplantation. Increased levels of most metabolites also associated with higher symptom burden. Our findings provide perspectives on the metabolic consequences of HF with potential implications for noninvasive monitoring and tailored therapy.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039248
Open AccessMetabolite Profiles of Heart Failure, Central Hemodynamic Derangement, and Response to Heart Transplantation
Background: Heart failure (HF) is characterized by hemodynamic derangements that are likely to mediate systemic metabolic perturbations but limited data are available. Plasma metabolite profiling provides opportunities for comprehensive investigation of such perturbations. Here, we aimed to characterize plasma profiles that associate with HF and their relationship with central hemodynamics, symptom burden, and response to restoration of cardiac function by heart transplantation. Methods: Untargeted metabolite profiling was conducted with mass spectrometry in 2 independent case–control samples. Results: In total, 89 of 797 studied metabolites were significantly associated with HF in both cohorts with concordant directionality. Amino acid, carbohydrate, and nucleotide metabolites were enriched for association with HF and were consistently increased in HF cases. A subset of patients with advanced HF subsequently underwent heart transplantation, after which 17 of the 89 metabolites returned significantly toward healthy control levels. These 17 metabolites represent increased catecholamine and heme metabolism, conjugated bile acids, kynurenine pathway mediators, spermidine metabolism, and allantoin, as well as tricarboxylic acid cycle and glycolysis intermediates. Most of these metabolites associated with symptom burden and at least 1 of 12 central hemodynamic parameters, primarily relating to either increased systemic or pulmonary venous congestion, lower cardiac output, or lower left ventricular stroke work. Conclusions: We comprehensively identified metabolite profiles associated with HF and central hemodynamics that reverse by cardiac transplantation. Increased levels of most metabolites also associated with higher symptom burden. Our findings provide perspectives on the metabolic consequences of HF with potential implications for noninvasive monitoring and tailored therapy.
- Open Access
- 5 June 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (5) , 897-906
Telemonitored standardized titration for heart failure with reduced ejection fraction, an open clinical cohort study
Aims: To evaluate feasibility, efficacy, and safety of standardized medical titration at home using telemonitoring. Treatment for heart failure with reduced ejection fraction (HFrEF) has advanced rapidly, emphasizing swift initiation and titration of guideline-directed medical therapy (GDMT) to improve outcomes. Implementing this in practice remains a significant challenge for healthcare. This study proposes a standardized home-based titration process incorporating home-based monitoring (HBM) to enhance GDMT titration, reduce delays, and limit the need for in-clinic assessment visits. Methods and results: 60 patients were enrolled in this open cohort study. Standardized pre-specified titration schedules in combination with HBM were evaluated. Outcome measures included the time to optimal medical therapy (OMT), doses of GDMT at 8 weeks and 6 months, and safety evaluation through adverse events. The median time to OMT was 48 days (IQR 42–60). All participants achieved OMT within 6 months. At 8 weeks, 73%, 85%, and 88% had reached target doses for beta-blockers, ACE inhibitors, and mineral receptor antagonists, respectively. All participants reached SGLT2i target dosage. By 6 months, 62%, 73%, 80%, and 97% were on target doses for these medications, and 43% had achieved target doses for all four GDMT drugs. No serious adverse events occurred during titration. Conclusion: We present a novel and promising approach for achieving OMT and high GDMT doses in patients with HFrEF. The utilization of standardized protocols has the potential to optimize the titration process of GDMT, and with HBM support, it can be accomplished with few in-clinic visits.
- 5 June 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (5) , 897-906
Open AccessTelemonitored standardized titration for heart failure with reduced ejection fraction, an open clinical cohort study
Aims: To evaluate feasibility, efficacy, and safety of standardized medical titration at home using telemonitoring. Treatment for heart failure with reduced ejection fraction (HFrEF) has advanced rapidly, emphasizing swift initiation and titration of guideline-directed medical therapy (GDMT) to improve outcomes. Implementing this in practice remains a significant challenge for healthcare. This study proposes a standardized home-based titration process incorporating home-based monitoring (HBM) to enhance GDMT titration, reduce delays, and limit the need for in-clinic assessment visits. Methods and results: 60 patients were enrolled in this open cohort study. Standardized pre-specified titration schedules in combination with HBM were evaluated. Outcome measures included the time to optimal medical therapy (OMT), doses of GDMT at 8 weeks and 6 months, and safety evaluation through adverse events. The median time to OMT was 48 days (IQR 42–60). All participants achieved OMT within 6 months. At 8 weeks, 73%, 85%, and 88% had reached target doses for beta-blockers, ACE inhibitors, and mineral receptor antagonists, respectively. All participants reached SGLT2i target dosage. By 6 months, 62%, 73%, 80%, and 97% were on target doses for these medications, and 43% had achieved target doses for all four GDMT drugs. No serious adverse events occurred during titration. Conclusion: We present a novel and promising approach for achieving OMT and high GDMT doses in patients with HFrEF. The utilization of standardized protocols has the potential to optimize the titration process of GDMT, and with HBM support, it can be accomplished with few in-clinic visits.
- Open Access
- 10 March 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (6) , 775-783
EMD missense variant causes X-linked isolated dilated cardiomyopathy with myocardial emerin deficiency
Pathogenic variants in the EMD gene cause X-linked Emery–Dreifuss muscular dystrophy type 1 (EDMD1), typically presenting with joint contractures and skeletal muscle atrophy, followed by atrial arrhythmias, cardiac conduction defects, and atrial dilatation. Although an association with isolated dilated cardiomyopathy (DCM) has been suggested, evidence is currently insufficient to verify the gene-disease association. We investigated the causality of a missense variant, c.23C>G, p.Ser8Trp, in EMD in a large family with a history of DCM and suspected sudden cardiac death (SCD) in males. DCM was diagnosed in six hemizygous males aged 36–50 and detailed phenotyping identified end-stage heart failure, cardiac conduction defects, and ventricular arrhythmias as prominent features. Cardiac magnetic resonance imaging showed late gadolinium enhancement with mixed ischemic and non-ischemic patterns. Muscular dystrophy was absent in all six males, of whom five underwent neuromuscular examination including serum-creatine kinase measurement. Immunohistochemical analysis showed greatly reduced levels of emerin in both cardiac and skeletal muscle samples. The EMD variant c.23C>G co-segregated with DCM, with an estimated LOD score of 3.9 and full-likelihood Bayes factor of >2500:1 in favor of causality. Among the 17 heterozygous females, ages 20–87, one developed DCM at age 72. We concluded that the EMD c.23C>G missense variant is associated with DCM in the absence of muscular dystrophy, thereby providing new evidence of isolated DCM as a distinct cardiac EMD-phenotype, separate from EDMD1. The phenotypic similarities with LMNA-DCM, with a high risk of cardiac conduction defects and ventricular arrhythmias, might warrant early interventions to prevent SCD.
- 10 March 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (6) , 775-783
Open AccessEMD missense variant causes X-linked isolated dilated cardiomyopathy with myocardial emerin deficiency
Pathogenic variants in the EMD gene cause X-linked Emery–Dreifuss muscular dystrophy type 1 (EDMD1), typically presenting with joint contractures and skeletal muscle atrophy, followed by atrial arrhythmias, cardiac conduction defects, and atrial dilatation. Although an association with isolated dilated cardiomyopathy (DCM) has been suggested, evidence is currently insufficient to verify the gene-disease association. We investigated the causality of a missense variant, c.23C>G, p.Ser8Trp, in EMD in a large family with a history of DCM and suspected sudden cardiac death (SCD) in males. DCM was diagnosed in six hemizygous males aged 36–50 and detailed phenotyping identified end-stage heart failure, cardiac conduction defects, and ventricular arrhythmias as prominent features. Cardiac magnetic resonance imaging showed late gadolinium enhancement with mixed ischemic and non-ischemic patterns. Muscular dystrophy was absent in all six males, of whom five underwent neuromuscular examination including serum-creatine kinase measurement. Immunohistochemical analysis showed greatly reduced levels of emerin in both cardiac and skeletal muscle samples. The EMD variant c.23C>G co-segregated with DCM, with an estimated LOD score of 3.9 and full-likelihood Bayes factor of >2500:1 in favor of causality. Among the 17 heterozygous females, ages 20–87, one developed DCM at age 72. We concluded that the EMD c.23C>G missense variant is associated with DCM in the absence of muscular dystrophy, thereby providing new evidence of isolated DCM as a distinct cardiac EMD-phenotype, separate from EDMD1. The phenotypic similarities with LMNA-DCM, with a high risk of cardiac conduction defects and ventricular arrhythmias, might warrant early interventions to prevent SCD.
- Open Access
- 29 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (23) , e035763
Out‐of‐Hospital Cardiac Arrest: Does a History of Myocarditis/Perimyocarditis Affect the Outcome? A Swedish Nationwide Study
Background: Acute myocarditis/perimyocarditis presents with a variable prognosis ranging from complete recovery to end‐stage heart failure (HF), sudden cardiac arrest, and death. The relationship between a prior history of myocarditis/perimyocarditis and outcomes in out‐of‐hospital cardiac arrest remains unclear. Methods and Results: Using the SCRR (Swedish Cardiopulmonary Resuscitation Registry), we analyzed 54 568 cases of out‐of‐hospital cardiac arrest from 2010 to 2020 where cardiopulmonary resuscitation was attempted. Patients with a history of myocarditis/perimyocarditis were compared with those without in terms of characteristics and survival. Four hundred ninety‐eight patients (0.9%) had a history of myocarditis/perimyocarditis. These patients were predominantly men (73.8%), had an average age of 68 years, displayed a higher prevalence of cardiovascular comorbidities, and more frequently displayed shockable initial rhythms (28.7% versus 23.1%). Prior myocarditis/pericarditis did not correlate with worse short‐term (odds ratio [OR], 0.91 [95% CI, 0.61–1.33]) or long‐term survival (hazard ratio [HR], 1.01 [95% CI, 0.91–1.13]). Patients with myocarditis/perimyocarditis with concomitant HF showed worse long‐term survival in unadjusted analyses. Adjusted analyses confirmed that absence of HF was linked to improved short‐term survival (OR, 1.46 [95% CI, 1.32–1.62]), whereas prevalence of HF was a predictor for worsened long‐term survival (HR, 0.91 [95% CI, 0.91–0.95]) after out‐of‐hospital cardiac arrest. Analyses were adjusted for myocarditis/perimyocarditis, sex, age, HF, time to cardiopulmonary resuscitation start, and initial rhythm. Conclusions: Prior myocarditis/perimyocarditis per se did not contribute to a worsened outcome following out‐of‐hospital cardiac arrest. However, the presence of concomitant HF was linked to unfavorable short‐ and long‐term outcomes.
- 29 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (23) , e035763
Open AccessOut‐of‐Hospital Cardiac Arrest: Does a History of Myocarditis/Perimyocarditis Affect the Outcome? A Swedish Nationwide Study
Background: Acute myocarditis/perimyocarditis presents with a variable prognosis ranging from complete recovery to end‐stage heart failure (HF), sudden cardiac arrest, and death. The relationship between a prior history of myocarditis/perimyocarditis and outcomes in out‐of‐hospital cardiac arrest remains unclear. Methods and Results: Using the SCRR (Swedish Cardiopulmonary Resuscitation Registry), we analyzed 54 568 cases of out‐of‐hospital cardiac arrest from 2010 to 2020 where cardiopulmonary resuscitation was attempted. Patients with a history of myocarditis/perimyocarditis were compared with those without in terms of characteristics and survival. Four hundred ninety‐eight patients (0.9%) had a history of myocarditis/perimyocarditis. These patients were predominantly men (73.8%), had an average age of 68 years, displayed a higher prevalence of cardiovascular comorbidities, and more frequently displayed shockable initial rhythms (28.7% versus 23.1%). Prior myocarditis/pericarditis did not correlate with worse short‐term (odds ratio [OR], 0.91 [95% CI, 0.61–1.33]) or long‐term survival (hazard ratio [HR], 1.01 [95% CI, 0.91–1.13]). Patients with myocarditis/perimyocarditis with concomitant HF showed worse long‐term survival in unadjusted analyses. Adjusted analyses confirmed that absence of HF was linked to improved short‐term survival (OR, 1.46 [95% CI, 1.32–1.62]), whereas prevalence of HF was a predictor for worsened long‐term survival (HR, 0.91 [95% CI, 0.91–0.95]) after out‐of‐hospital cardiac arrest. Analyses were adjusted for myocarditis/perimyocarditis, sex, age, HF, time to cardiopulmonary resuscitation start, and initial rhythm. Conclusions: Prior myocarditis/perimyocarditis per se did not contribute to a worsened outcome following out‐of‐hospital cardiac arrest. However, the presence of concomitant HF was linked to unfavorable short‐ and long‐term outcomes.
- Open Access
- 30 October 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002937
Predicting troponin biomarker elevation from electrocardiograms using a deep neural network
Background: Elevated troponin levels are a sensitive biomarker for cardiac injury. The quick and reliable prediction of troponin elevation for patients with chest pain from readily available ECGs may pose a valuable time-saving diagnostic tool during decision-making concerning this patient population. Methods and results: The data used included 15 856 ECGs from patients presenting to the emergency rooms with chest pain or dyspnoea at two centres in Sweden from 2015 to June 2023. All patients had high-sensitivity troponin test results within 6 hours after 12-lead ECG. Both troponin I (TnI) and TnT were used, with biomarker-specific cut-offs and sex-specific cut-offs for TnI. On this dataset, a residual convolutional neural network (ResNet) was trained 10 times, each on a unique split of the data. The final model achieved an average area under the curve for the receiver operating characteristic curve of 0.7717 (95% CI±0.0052), calibration curve analysis revealed a mean slope of 1.243 (95% CI±0.075) and intercept of −0.073 (95% CI±0.034), indicating a good correlation between prediction and ground truth. Post-classification, tuned for F1 score, accuracy was 71.43% (95% CI±1.28), with an F1 score of 0.5642 (95% CI±0.0052) and a negative predictive value of 0.8660 (95% CI±0.0048), respectively. The ResNet displayed comparable or surpassing metrics to prior presented models. Conclusion: The model exhibited clinically meaningful performance, notably its high negative predictive accuracy. Therefore, clinical use of comparable neural networks in first-line, quick-response triage of patients with chest pain or dyspnoea appears as a valuable option in future medical practice.
- 30 October 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002937
Open AccessPredicting troponin biomarker elevation from electrocardiograms using a deep neural network
Background: Elevated troponin levels are a sensitive biomarker for cardiac injury. The quick and reliable prediction of troponin elevation for patients with chest pain from readily available ECGs may pose a valuable time-saving diagnostic tool during decision-making concerning this patient population. Methods and results: The data used included 15 856 ECGs from patients presenting to the emergency rooms with chest pain or dyspnoea at two centres in Sweden from 2015 to June 2023. All patients had high-sensitivity troponin test results within 6 hours after 12-lead ECG. Both troponin I (TnI) and TnT were used, with biomarker-specific cut-offs and sex-specific cut-offs for TnI. On this dataset, a residual convolutional neural network (ResNet) was trained 10 times, each on a unique split of the data. The final model achieved an average area under the curve for the receiver operating characteristic curve of 0.7717 (95% CI±0.0052), calibration curve analysis revealed a mean slope of 1.243 (95% CI±0.075) and intercept of −0.073 (95% CI±0.034), indicating a good correlation between prediction and ground truth. Post-classification, tuned for F1 score, accuracy was 71.43% (95% CI±1.28), with an F1 score of 0.5642 (95% CI±0.0052) and a negative predictive value of 0.8660 (95% CI±0.0048), respectively. The ResNet displayed comparable or surpassing metrics to prior presented models. Conclusion: The model exhibited clinically meaningful performance, notably its high negative predictive accuracy. Therefore, clinical use of comparable neural networks in first-line, quick-response triage of patients with chest pain or dyspnoea appears as a valuable option in future medical practice.
- 22 December 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (7) , 812-821
Long-term secondary prevention and outcome following acute coronary syndrome: real-world results from the Swedish Primary Care Cardiovascular Database
Aims: Most studies of treatment adherence after acute coronary syndrome (ACS) are based on prescribed drugs and lack long-term follow-up or consecutive data on risk factor control. We studied the long-term treatment adherence, risk factor control, and its association to recurrent ACS and death. Methods and results: We retrospectively included 3765 patients (mean age 75 years, 40% women) with incident ACS from 1 January 2006 until 31 December 2010 from the Swedish Primary Care Cardiovascular Database of Skaraborg. All patients were followed until 31 December 2014 or death. We recorded blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), recurrent ACS, and death. We used data on dispensed drugs to calculate the proportion of days covered for secondary prevention medications. Cox regressions were used to analyse the association of achieved BP and LDL-C to recurrent ACS and death. The median follow-up time was 4.8 years. The proportion of patients that reached BP of <140/90 mm Hg was 58% at Year 1 and 66% at Year 8. 65% of the patients reached LDL-C of <2.5 mmol/L at Year 1 and 56% at Year 8; however, adherence to statins varied from 43% to 60%. Only 62% of the patients had yearly measured BP, and only 28% yearly measured LDL-C. Systolic BP was not associated with a higher risk of recurrent ACS or death. Low-density lipoprotein cholesterol of 3.0 mmol/L was associated with a higher risk of recurrent ACS {hazard ratio [HR] 1.19 [95% confidence interval (CI) 1.00–1.40]} and death HR [1.26 (95% CI 1.08–1.47)] compared with an LDL-C of 1.8 mmol/L. Conclusion: This observational long-term real-world study demonstrates low drug adherence and potential for improvement of risk factors after ACS. Furthermore, the study confirms that uncontrolled LDL-C is associated with adverse outcome even in this older population.
- 22 December 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (7) , 812-821
Long-term secondary prevention and outcome following acute coronary syndrome: real-world results from the Swedish Primary Care Cardiovascular Database
Aims: Most studies of treatment adherence after acute coronary syndrome (ACS) are based on prescribed drugs and lack long-term follow-up or consecutive data on risk factor control. We studied the long-term treatment adherence, risk factor control, and its association to recurrent ACS and death. Methods and results: We retrospectively included 3765 patients (mean age 75 years, 40% women) with incident ACS from 1 January 2006 until 31 December 2010 from the Swedish Primary Care Cardiovascular Database of Skaraborg. All patients were followed until 31 December 2014 or death. We recorded blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), recurrent ACS, and death. We used data on dispensed drugs to calculate the proportion of days covered for secondary prevention medications. Cox regressions were used to analyse the association of achieved BP and LDL-C to recurrent ACS and death. The median follow-up time was 4.8 years. The proportion of patients that reached BP of <140/90 mm Hg was 58% at Year 1 and 66% at Year 8. 65% of the patients reached LDL-C of <2.5 mmol/L at Year 1 and 56% at Year 8; however, adherence to statins varied from 43% to 60%. Only 62% of the patients had yearly measured BP, and only 28% yearly measured LDL-C. Systolic BP was not associated with a higher risk of recurrent ACS or death. Low-density lipoprotein cholesterol of 3.0 mmol/L was associated with a higher risk of recurrent ACS {hazard ratio [HR] 1.19 [95% confidence interval (CI) 1.00–1.40]} and death HR [1.26 (95% CI 1.08–1.47)] compared with an LDL-C of 1.8 mmol/L. Conclusion: This observational long-term real-world study demonstrates low drug adherence and potential for improvement of risk factors after ACS. Furthermore, the study confirms that uncontrolled LDL-C is associated with adverse outcome even in this older population.
- Open Access
- 17 April 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Differences in phenotypes, symptoms, and survival in patients with cardiomyopathy—a prospective observational study from the Sahlgrenska CardioMyoPathy Centre
Introduction: Cardiomyopathy is the fourth most common cause of heart failure. The spectrum of cardiomyopathies may be impacted by changes in environmental factors and the prognosis may be influenced by modern treatment. The aim of this study is to create a prospective clinical cohort, the Sahlgrenska CardioMyoPathy Centre (SCMPC) study, and compare patients with cardiomyopathies in terms of phenotype, symptoms, and survival.Methods: The SCMPC study was founded in 2018 by including patients with all types of suspected cardiomyopathies. This study included data on patient characteristics, background, family history, symptoms, diagnostic examinations, and treatment including heart transplantation and mechanical circulatory support (MCS). Patients were categorized by the type of cardiomyopathy on the basis of the diagnostic criteria laid down by the European Society of Cardiology (ESC) working group on myocardial and pericardial diseases. The primary outcomes were death, heart transplantation, or MCS, analyzed by Kaplan–Meier and Cox proportional regression, adjusted for age, gender, LVEF and QRS width on ECG in milliseconds.Results: In all, 461 patients and 73.1% men with a mean age of 53.6 ± 16 years were included in the study. The most common diagnosis was dilated cardiomyopathy (DCM), followed by cardiac sarcoidosis and myocarditis. Dyspnea was the most common initial symptom in patients with DCM and amyloidosis, while patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) presented with ventricular arrythmias. Patients with ARVC, left-ventricular non-compaction cardiomyopathy (LVNC), hypertrophic cardiomyopathy (HCM), and DCM had the longest time from the debut of symptoms until inclusion in the study. Overall, 86% of the patients survived without heart transplantation or MCS after 2.5 years. The primary outcome differed among the cardiomyopathies, where the worst prognosis was reported for ARVC, LVNC, and cardiac amyloidosis. In a Cox regression analysis, it was found that ARVC and LVNC were independently associated with an increased risk of death, heart transplantation, or MCS compared with DCM. Further, female gender, a lower LVEF, and a wider QRS width were associated with an increased risk of the primary outcome.Conclusions: The SCMPC database offers a unique opportunity to explore the spectrum of cardiomyopathies over time. There is a large difference in characteristics and symptoms at debut and a remarkable difference in outcome, where the worst prognosis was reported for ARVC, LVNC, and cardiac amyloidosis.
- 17 April 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Open AccessDifferences in phenotypes, symptoms, and survival in patients with cardiomyopathy—a prospective observational study from the Sahlgrenska CardioMyoPathy Centre
Introduction: Cardiomyopathy is the fourth most common cause of heart failure. The spectrum of cardiomyopathies may be impacted by changes in environmental factors and the prognosis may be influenced by modern treatment. The aim of this study is to create a prospective clinical cohort, the Sahlgrenska CardioMyoPathy Centre (SCMPC) study, and compare patients with cardiomyopathies in terms of phenotype, symptoms, and survival.Methods: The SCMPC study was founded in 2018 by including patients with all types of suspected cardiomyopathies. This study included data on patient characteristics, background, family history, symptoms, diagnostic examinations, and treatment including heart transplantation and mechanical circulatory support (MCS). Patients were categorized by the type of cardiomyopathy on the basis of the diagnostic criteria laid down by the European Society of Cardiology (ESC) working group on myocardial and pericardial diseases. The primary outcomes were death, heart transplantation, or MCS, analyzed by Kaplan–Meier and Cox proportional regression, adjusted for age, gender, LVEF and QRS width on ECG in milliseconds.Results: In all, 461 patients and 73.1% men with a mean age of 53.6 ± 16 years were included in the study. The most common diagnosis was dilated cardiomyopathy (DCM), followed by cardiac sarcoidosis and myocarditis. Dyspnea was the most common initial symptom in patients with DCM and amyloidosis, while patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) presented with ventricular arrythmias. Patients with ARVC, left-ventricular non-compaction cardiomyopathy (LVNC), hypertrophic cardiomyopathy (HCM), and DCM had the longest time from the debut of symptoms until inclusion in the study. Overall, 86% of the patients survived without heart transplantation or MCS after 2.5 years. The primary outcome differed among the cardiomyopathies, where the worst prognosis was reported for ARVC, LVNC, and cardiac amyloidosis. In a Cox regression analysis, it was found that ARVC and LVNC were independently associated with an increased risk of death, heart transplantation, or MCS compared with DCM. Further, female gender, a lower LVEF, and a wider QRS width were associated with an increased risk of the primary outcome.Conclusions: The SCMPC database offers a unique opportunity to explore the spectrum of cardiomyopathies over time. There is a large difference in characteristics and symptoms at debut and a remarkable difference in outcome, where the worst prognosis was reported for ARVC, LVNC, and cardiac amyloidosis.
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Long-term risk factor control after acute coronary syndrome; results from the Swedish primary care cardiovascular database
Background: Most secondary prevention studies after acute coronary syndrome (ACS) have relatively short follow-up time, and less is known about long-term risk factor control in patients after ACS. Purpose: We aimed to study and describe the long-term risk factor control, treatment adherence and outcome after ACS. Methods: We identified 3765 patients (mean age 75 years, 40% women) with an incident ACS between 2006 and 2010 in the Swedish Primary Care Cardiovascular Database. All participants were followed from index ACS until 31 December 2014 or death. We annually recorded blood pressure, low density lipoprotein cholesterol (LDL-C), dispensed prescription of drugs, recurrent ACS, and death. Data were collected from electronic medical records at the primary care centres, the Swedish Prescribed Drug Register, the Swedish Patient Register, and the Cause of Death Register. We calculated annually proportion of days covered (PDC) for secondary prevention medication. PDC value of ≥80% was considered cut off for medication adherence. Results: The median follow-up time was 4.8 years (min 1.8 and max 8.0). 1890 new ACS-events were recorded during the follow up; the annual incidence of recurrent ACS was 17.3%, 12.9%, 8.9%, 8.0%, 7.6%, 6.5%, 5.2%, and 5.0% (for year 1 to year 8 respectively). 1859 (49.4%) patients died during the follow up. The annual incidence of death was 19.9%, 7.9%, 7.1%, 8.3%, 7.9%, 8.2%, 6.7%, and 6.4% (for year 1 to year 8 respectively). The annual proportion of patients that achieved the blood pressure target <140/90 mm Hg was 57.8%, 60.9%, 62.7%, 63.3%, 64.9%, 63.1%, 62.4%, and 66.1% (for year 1 to year 8 respectively). The annual mean number of antihypertensive medications for each patient was 1.5, 1.3, 1.3, 1.3, 1.4, 1.4, 1.4, and 1.5 (for year 1 to year 8 respectively). The annual proportion of patients that achieved LDL-C <1.8 mmol/L was 23.1%, 21.7%, 19.8%, 18.2%, 15.7%, 19.6%, 18.3%, and 16.7% (for year 1 to year 8 respectively). The annual proportion of patients in treatment with statins was 55.3%, 57.5%, 58.7%, 59.2%, 63.0%, 63.7%, 64.1%, and 67.7% (for year 1 to year 8 respectively). The annual proportion of patients in treatment with acetylsalicylic acid was 79.6%, 76.4%, 76.2%, 78.9%, 78.3%, 79.2%, and 80.8% % (for year 1 to year 8 respectively). The annual proportion of patients in treatment with P2Y12-inhibitors was 24.3%, 7.2%, 5.4%, 6.0%, 7.2%, 8.1%, 7.9% and 8.2% (for year 1 to year 8 respectively). Conclusion: This retrospective long-term real-world study from primary care demonstrates a large potential for improvement of risk factor control in patients after ACS. More specific, this study demonstrates underutilized treatment with antihypertensive medication and statins, while adherence to antiplatelet therapy was found to be high. Funding Acknowledgement: Type of funding sources: Private company. Main funding source(s): Astra Zeneca
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessLong-term risk factor control after acute coronary syndrome; results from the Swedish primary care cardiovascular database
Background: Most secondary prevention studies after acute coronary syndrome (ACS) have relatively short follow-up time, and less is known about long-term risk factor control in patients after ACS. Purpose: We aimed to study and describe the long-term risk factor control, treatment adherence and outcome after ACS. Methods: We identified 3765 patients (mean age 75 years, 40% women) with an incident ACS between 2006 and 2010 in the Swedish Primary Care Cardiovascular Database. All participants were followed from index ACS until 31 December 2014 or death. We annually recorded blood pressure, low density lipoprotein cholesterol (LDL-C), dispensed prescription of drugs, recurrent ACS, and death. Data were collected from electronic medical records at the primary care centres, the Swedish Prescribed Drug Register, the Swedish Patient Register, and the Cause of Death Register. We calculated annually proportion of days covered (PDC) for secondary prevention medication. PDC value of ≥80% was considered cut off for medication adherence. Results: The median follow-up time was 4.8 years (min 1.8 and max 8.0). 1890 new ACS-events were recorded during the follow up; the annual incidence of recurrent ACS was 17.3%, 12.9%, 8.9%, 8.0%, 7.6%, 6.5%, 5.2%, and 5.0% (for year 1 to year 8 respectively). 1859 (49.4%) patients died during the follow up. The annual incidence of death was 19.9%, 7.9%, 7.1%, 8.3%, 7.9%, 8.2%, 6.7%, and 6.4% (for year 1 to year 8 respectively). The annual proportion of patients that achieved the blood pressure target <140/90 mm Hg was 57.8%, 60.9%, 62.7%, 63.3%, 64.9%, 63.1%, 62.4%, and 66.1% (for year 1 to year 8 respectively). The annual mean number of antihypertensive medications for each patient was 1.5, 1.3, 1.3, 1.3, 1.4, 1.4, 1.4, and 1.5 (for year 1 to year 8 respectively). The annual proportion of patients that achieved LDL-C <1.8 mmol/L was 23.1%, 21.7%, 19.8%, 18.2%, 15.7%, 19.6%, 18.3%, and 16.7% (for year 1 to year 8 respectively). The annual proportion of patients in treatment with statins was 55.3%, 57.5%, 58.7%, 59.2%, 63.0%, 63.7%, 64.1%, and 67.7% (for year 1 to year 8 respectively). The annual proportion of patients in treatment with acetylsalicylic acid was 79.6%, 76.4%, 76.2%, 78.9%, 78.3%, 79.2%, and 80.8% % (for year 1 to year 8 respectively). The annual proportion of patients in treatment with P2Y12-inhibitors was 24.3%, 7.2%, 5.4%, 6.0%, 7.2%, 8.1%, 7.9% and 8.2% (for year 1 to year 8 respectively). Conclusion: This retrospective long-term real-world study from primary care demonstrates a large potential for improvement of risk factor control in patients after ACS. More specific, this study demonstrates underutilized treatment with antihypertensive medication and statins, while adherence to antiplatelet therapy was found to be high. Funding Acknowledgement: Type of funding sources: Private company. Main funding source(s): Astra Zeneca